472 related articles for article (PubMed ID: 25429712)
1. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
[TBL] [Abstract][Full Text] [Related]
2. Co-treatment with panitumumab and trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer.
Lindberg JM; Newhook TE; Adair SJ; Walters DM; Kim AJ; Stelow EB; Parsons JT; Bauer TW
Neoplasia; 2014 Jul; 16(7):562-71. PubMed ID: 25117978
[TBL] [Abstract][Full Text] [Related]
3. Cotargeting of epidermal growth factor receptor and PI3K overcomes PI3K-Akt oncogenic dependence in pancreatic ductal adenocarcinoma.
Wong MH; Xue A; Julovi SM; Pavlakis N; Samra JS; Hugh TJ; Gill AJ; Peters L; Baxter RC; Smith RC
Clin Cancer Res; 2014 Aug; 20(15):4047-58. PubMed ID: 24895459
[TBL] [Abstract][Full Text] [Related]
4. Monensin inhibits cell proliferation and tumor growth of chemo-resistant pancreatic cancer cells by targeting the EGFR signaling pathway.
Wang X; Wu X; Zhang Z; Ma C; Wu T; Tang S; Zeng Z; Huang S; Gong C; Yuan C; Zhang L; Feng Y; Huang B; Liu W; Zhang B; Shen Y; Luo W; Wang X; Liu B; Lei Y; Ye Z; Zhao L; Cao D; Yang L; Chen X; Haydon RC; Luu HH; Peng B; Liu X; He TC
Sci Rep; 2018 Dec; 8(1):17914. PubMed ID: 30559409
[TBL] [Abstract][Full Text] [Related]
5. Target therapies in pancreatic carcinoma.
Silvestris N; Gnoni A; Brunetti AE; Vincenti L; Santini D; Tonini G; Merchionne F; Maiello E; Lorusso V; Nardulli P; Azzariti A; Reni M
Curr Med Chem; 2014; 21(8):948-65. PubMed ID: 23992319
[TBL] [Abstract][Full Text] [Related]
6. Targeting EGFR in pancreatic cancer treatment.
Troiani T; Martinelli E; Capasso A; Morgillo F; Orditura M; De Vita F; Ciardiello F
Curr Drug Targets; 2012 Jun; 13(6):802-10. PubMed ID: 22458527
[TBL] [Abstract][Full Text] [Related]
7. Disclosure of erlotinib as a multikinase inhibitor in pancreatic ductal adenocarcinoma.
Conradt L; Godl K; Schaab C; Tebbe A; Eser S; Diersch S; Michalski CW; Kleeff J; Schnieke A; Schmid RM; Saur D; Schneider G
Neoplasia; 2011 Nov; 13(11):1026-34. PubMed ID: 22131878
[TBL] [Abstract][Full Text] [Related]
8. Rational combination of targeted therapies as a strategy to overcome the mechanisms of resistance to inhibitors of EGFR signaling.
Bianco R; Damiano V; Gelardi T; Daniele G; Ciardiello F; Tortora G
Curr Pharm Des; 2007; 13(33):3358-67. PubMed ID: 18045190
[TBL] [Abstract][Full Text] [Related]
9. Targeting Epidermal Growth Factor Receptor-Related Signaling Pathways in Pancreatic Cancer.
Philip PA; Lutz MP
Pancreas; 2015 Oct; 44(7):1046-52. PubMed ID: 26355547
[TBL] [Abstract][Full Text] [Related]
10. Mesothelin and TGF-α predict pancreatic cancer cell sensitivity to EGFR inhibitors and effective combination treatment with trametinib.
Poteet E; Liu D; Liang Z; Van Buren G; Chen C; Yao Q
PLoS One; 2019; 14(3):e0213294. PubMed ID: 30921351
[TBL] [Abstract][Full Text] [Related]
11. Targeting ErbB3-mediated stromal-epithelial interactions in pancreatic ductal adenocarcinoma.
Liles JS; Arnoletti JP; Kossenkov AV; Mikhaylina A; Frost AR; Kulesza P; Heslin MJ; Frolov A
Br J Cancer; 2011 Aug; 105(4):523-33. PubMed ID: 21792199
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
Harding J; Burtness B
Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
[TBL] [Abstract][Full Text] [Related]
13. Human pancreatic cancer stem cells are sensitive to dual inhibition of IGF-IR and ErbB receptors.
Urtasun N; Vidal-Pla A; Pérez-Torras S; Mazo A
BMC Cancer; 2015 Apr; 15():223. PubMed ID: 25886138
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal antibody therapies targeting pancreatic ductal adenocarcinoma.
Engelhardt K; Riley C; Cooke L; Mahadevan D
Curr Drug Discov Technol; 2006 Dec; 3(4):231-43. PubMed ID: 17430101
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib: the first biologic in the management of pancreatic cancer.
Saif MW
Expert Opin Pharmacother; 2008 Jun; 9(9):1595-607. PubMed ID: 18518788
[TBL] [Abstract][Full Text] [Related]
16. Survival benefit with proapoptotic molecular and pathologic responses from dual targeting of mammalian target of rapamycin and epidermal growth factor receptor in a preclinical model of pancreatic neuroendocrine carcinogenesis.
Chiu CW; Nozawa H; Hanahan D
J Clin Oncol; 2010 Oct; 28(29):4425-33. PubMed ID: 20823411
[TBL] [Abstract][Full Text] [Related]
17. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
18. Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions.
Zhang Y; Yang C; Cheng H; Fan Z; Huang Q; Lu Y; Fan K; Luo G; Jin K; Wang Z; Liu C; Yu X
J Hematol Oncol; 2018 Jan; 11(1):14. PubMed ID: 29386069
[TBL] [Abstract][Full Text] [Related]
19. Alantolactone sensitizes human pancreatic cancer cells to EGFR inhibitors through the inhibition of STAT3 signaling.
Zheng H; Yang L; Kang Y; Chen M; Lin S; Xiang Y; Li C; Dai X; Huang X; Liang G; Zhao C
Mol Carcinog; 2019 Apr; 58(4):565-576. PubMed ID: 30520143
[TBL] [Abstract][Full Text] [Related]
20. The ERBB receptor inhibitor dacomitinib suppresses proliferation and invasion of pancreatic ductal adenocarcinoma cells.
Momeny M; Esmaeili F; Hamzehlou S; Yousefi H; Javadikooshesh S; Vahdatirad V; Alishahi Z; Mousavipak SH; Bashash D; Dehpour AR; Tavangar SM; Tavakkoly-Bazzaz J; Haddad P; Kordbacheh F; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Cell Oncol (Dordr); 2019 Aug; 42(4):491-504. PubMed ID: 31025257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
